Phase 2
Idiopathic Pulmonary Fibrosis
Intervention Type
Intravenous (IV) Injection
Funder Type

Drug Details

PRM-151 is an anti-fibrotic immunomodulator being developed for treatment of fibrotic diseases.

Study Purpose

The Phase 2 clinical trial to evaluate PRM-151 in IPF is a randomized, double-blind, placebo-controlled, pilot study designed to determine efficacy and safety of PRM-151 in patients with Idiopathic Pulmonary Fibrosis (IPF). Patients meeting the eligibility criteria for the study will be randomized to PRM-151 10 mg/kg every 4 weeks or placebo. Efficacy will be evaluated through pulmonary function tests (PFTs), high resolution CT (HRCT), 6-minute walk test (6MWT), and Patient Reported Outcomes (PROs). The primary objective is to determine the effect size of PRM-151 relative to placebo in change from Baseline to Week 28 in mean FVC% predicted, pooling patients on a stable dose of pirfenidone or nintedanib and patients not on other treatment for IPF. 

This drug has no clinical trials actively recruiting patients at this time.


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >